Antimicrobial resistance (AMR) remains one of the most serious long-term threats to global and UK healthcare systems. While it rarely dominates headlines in the same way as acute outbreaks, its cumulative impact is profound – gradually reducing the effectiveness of antibiotics and increasing risks across routine and complex medical care.
In the UK, AMR is already influencing clinical practice within the NHS, shaping regulatory priorities, and driving national policy responses led by public health bodies.
A slow-moving crisis with wide-reaching impact
AMR occurs when microorganisms evolve to resist antimicrobial treatments, making infections harder to treat and increasing the risk of complications, prolonged illness, and mortality.
In practical terms, this affects everything from routine surgery and cancer treatment to intensive care and neonatal medicine – all of which depend on effective antibiotics to prevent and treat infection.
Within the UK, surveillance data continues to show concerning levels of resistant infections, particularly in healthcare-associated settings. While stewardship efforts have helped slow inappropriate prescribing, resistance continues to rise in certain pathogen groups.
The UK response: stewardship and surveillance
The UK is widely recognised for its leadership in antimicrobial stewardship. The NHS has implemented long-standing initiatives to reduce unnecessary antibiotic prescribing and improve infection prevention and control across healthcare settings.
The UK Health Security Agency (UKHSA) plays a central role in monitoring resistance trends, supporting outbreak detection, and providing national guidance to clinicians and healthcare organisations.
At a policy level, the UK’s national action plan on AMR follows a “One Health” approach, recognising the interconnected role of human health, animal health, agriculture, and the environment in driving resistance.
Despite these efforts, maintaining progress remains challenging – particularly in settings where clinical uncertainty leads to precautionary antibiotic use.
The innovation challenge in antibiotics
One of the most persistent issues in AMR is the lack of commercial incentive for antibiotic development.
Unlike medicines for chronic conditions, antibiotics are typically used for short courses and are deliberately conserved to preserve effectiveness. This limits commercial returns and has contributed to a relatively weak late-stage antibiotic pipeline.
As a result, policymakers and regulators are increasingly exploring alternative models, including new reimbursement approaches and incentives designed to support antimicrobial innovation while ensuring responsible use.
Regulation and access: a delicate balance
Regulators face a unique challenge in AMR: enabling faster access to new antibiotics while ensuring they are used appropriately to prevent further resistance.
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) works alongside international partners to assess new antimicrobial therapies and support safe access pathways.
Post-market controls, prescribing restrictions, and enhanced surveillance are increasingly important tools in ensuring that innovation does not accelerate resistance.
Diagnostics and clinical practice
Improving diagnostic capability is central to tackling AMR. Faster identification of pathogens enables more targeted treatment, reducing reliance on broad-spectrum antibiotics.
Within the NHS, progress is being made in integrating rapid diagnostics into clinical pathways, but access and adoption remain variable across settings.
Clinical behaviour also plays a major role. Prescribing practices, patient expectations, and time pressures can all influence antibiotic use, highlighting the need for continued education and system-level support.
Why AMR remains a strategic priority
Unlike infectious disease outbreaks, AMR is a gradual and evolving threat, but its long-term implications for healthcare are significant.
For the NHS, rising resistance could increase hospital stays, complicate routine procedures, and place additional pressure on already stretched services. For healthcare systems more broadly, it represents a fundamental challenge to the safety and sustainability of modern medicine.
A shared responsibility
Tackling AMR requires sustained collaboration between government, regulators, healthcare providers, and industry.
The UK is well positioned through its surveillance systems, stewardship frameworks, and scientific expertise. However, long-term progress will depend on continued investment in innovation, improved diagnostics, and coordinated global action.
AMR is often described as a “silent pandemic” – and while its progression is gradual, its consequences are potentially transformative for healthcare systems worldwide.
Back to News + Insights